February 24, 2005 -- Some were surprised when the FDA advisory committee supported keeping Celebrex and Bextra on the market. While the COX-2 saga will continue to develop, the fundamental issues remain unchanged as ever. There are several lessons to be learned from this story. Perhaps most important is Direct-To-Consumer advertising, which is crucial to the blockbuster mentality of big pharma. Will the COX-2 debacle affect this phenomenon?
